[go: up one dir, main page]

MX2019003938A - Compuestos espirociclicos. - Google Patents

Compuestos espirociclicos.

Info

Publication number
MX2019003938A
MX2019003938A MX2019003938A MX2019003938A MX2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A
Authority
MX
Mexico
Prior art keywords
spirocyclic compounds
compounds
spirocyclic
ameliorating
treating
Prior art date
Application number
MX2019003938A
Other languages
English (en)
Inventor
Kahraman Mehmet
Qinhua Huang Peter
Duane Bunker Kevin
Original Assignee
Zeno Royalties & Milestones Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalties & Milestones Llc filed Critical Zeno Royalties & Milestones Llc
Publication of MX2019003938A publication Critical patent/MX2019003938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente descripción se describen compuestos espirocíclicos, junto con composiciones farmacéuticas y métodos para mejorar y/o tratar un cáncer descrito en la presente descripción con uno o más de los compuestos descritos en la presente descripción.
MX2019003938A 2016-10-05 2017-10-03 Compuestos espirociclicos. MX2019003938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (1)

Publication Number Publication Date
MX2019003938A true MX2019003938A (es) 2019-06-10

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003938A MX2019003938A (es) 2016-10-05 2017-10-03 Compuestos espirociclicos.

Country Status (13)

Country Link
US (2) US10934304B2 (es)
EP (1) EP3523306A4 (es)
JP (2) JP6949952B2 (es)
KR (1) KR20190075931A (es)
CN (1) CN109890827A (es)
AU (1) AU2017339890A1 (es)
BR (1) BR112019005305A2 (es)
CA (1) CA3037064A1 (es)
IL (1) IL265752A (es)
MX (1) MX2019003938A (es)
RU (1) RU2019107667A (es)
TW (1) TW201817732A (es)
WO (1) WO2018067512A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
KR20170132307A (ko) 2015-04-03 2017-12-01 카리라 파마슈티컬스, 아이앤씨. 스피로 고리 화합물
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
DK3846904T3 (da) * 2018-09-07 2023-08-21 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) * 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2025096858A1 (en) * 2023-10-31 2025-05-08 C4 Therapeutics, Inc. Compounds for the degradation of mutant braf

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
WO2007070398A1 (en) * 2005-12-13 2007-06-21 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
CN101772501A (zh) * 2007-06-18 2010-07-07 先灵公司 杂环化合物及其作为erk抑制剂的用途
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8664213B2 (en) * 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
WO2014149819A1 (en) 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
ES2700200T3 (es) 2014-12-22 2019-02-14 Lilly Co Eli Inhibidores de ERK
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
KR20170132307A (ko) * 2015-04-03 2017-12-01 카리라 파마슈티컬스, 아이앤씨. 스피로 고리 화합물

Also Published As

Publication number Publication date
CN109890827A (zh) 2019-06-14
RU2019107667A (ru) 2020-11-06
WO2018067512A1 (en) 2018-04-12
NZ751398A (en) 2021-03-26
WO2018067512A8 (en) 2018-11-01
IL265752A (en) 2019-06-30
EP3523306A1 (en) 2019-08-14
JP2021193138A (ja) 2021-12-23
US20200207776A1 (en) 2020-07-02
CA3037064A1 (en) 2018-04-12
JP6949952B2 (ja) 2021-10-13
EP3523306A4 (en) 2020-05-06
KR20190075931A (ko) 2019-07-01
US10934304B2 (en) 2021-03-02
RU2019107667A3 (es) 2021-01-27
AU2017339890A1 (en) 2019-04-11
US20210115058A1 (en) 2021-04-22
BR112019005305A2 (pt) 2019-07-02
TW201817732A (zh) 2018-05-16
JP2019534261A (ja) 2019-11-28

Similar Documents

Publication Publication Date Title
MX2019003938A (es) Compuestos espirociclicos.
ZA201807399B (en) Egfr inhibitor compounds
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX2017001587A (es) Terapia de combinacion para tratar un paramixovirus.
MX379622B (es) Compuestos espirociclicos
MX2018003472A (es) Moduladores de la expresion de kras.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MY187540A (en) Compounds active towards bromodomains
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX2017014436A (es) Compuestos biciclicos.
MX2021009899A (es) Administracion y dosificacion de diaminofenotiazinas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
WO2016130581A3 (en) Combination cancer therapy
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.